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Abstract
Background
Scavenger Receptors (SRs) from the host’s innate immune system are known to bind multi-
ple ligands to promote the removal of non-self or altered-self targets. CD5 and CD6 are two
highly homologous class I SRs mainly expressed on all T cells and the B1a cell subset, and
involved in the fine tuning of activation and differentiation signals delivered by the antigen-
specific receptors (TCR and BCR, respectively), to which they physically associate. Addi-
tionally, CD5 and CD6 have been shown to interact with and sense the presence of con-
served pathogen-associated structures from bacteria, fungi and/or viruses.
Methodology/Principal findings
We report herein the interaction of CD5 and CD6 lymphocyte surface receptors with Echino-
coccus granulosus sensu lato (s.l.). Binding studies show that both soluble and membrane-
bound forms of CD5 and CD6 bind to intact viable protoscoleces from E. granulosus s.l.
through recognition of metaperiodate-resistant tegumental components. Proteomic analy-
ses allowed identification of thioredoxin peroxidase for CD5, and peptidyl-prolyl cis-trans
isomerase (cyclophilin) and endophilin B1 (antigen P-29) for CD6, as their potential interac-
tors. Further in vitro assays demonstrate that membrane-bound or soluble CD5 and CD6
forms differentially modulate the pro- and anti-inflammatory cytokine release induced follow-
ing peritoneal cells exposure to E. granulosus s.l. tegumental components. Importantly, pro-
phylactic infusion of soluble CD5 or CD6 significantly ameliorated the infection outcome in
the mouse model of secondary cystic echinococcosis.
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Conclusions/Significance
Taken together, the results expand the pathogen binding properties of CD5 and CD6 and
provide novel evidence for their therapeutic potential in human cystic echinococcosis.
Author summary
Scavenger Receptors (SRs) are constituents of host’s innate immune system able to sense
and remove altered-self and/or pathogen components. Data on their interaction with hel-
minth parasites is scarce. In this work, we describe that CD5 and CD6 -two lymphoid SRs
previously reported to interact with conserved structures from bacteria, fungi and viruses-
recognize tegumental components in the cestode parasite Echinococcus granulosus sensu
lato (s.l.). Moreover, both receptors differentially modulate the cytokine release by host
cells exposed to E. granulosus s.l. tegumental components. Importantly, the infusion of
soluble forms of CD5 or CD6 improve infection outcomes in a murine model of second-
ary cystic echinococcosis. In summary, our results expand the pathogen binding proper-
ties of CD5 and CD6 and suggest their therapeutic potential against helminth infections.
Introduction
The mammalian innate immune system relies on a limited number of germline-encoded and
non-clonally distributed receptors for pathogen recognition, which have evolved to identify
the so called pathogen associated molecular patterns (PAMPs): conserved microbial structures,
essential for their survival and not shared by the host, such as lipopolysaccharide (LPS) from
Gram-negative bacteria, lipotheichoic acid (LTA) from Gram-positive bacteria, lipoarabino-
mannan from mycobacteria, mannan from fungi, chitin from parasites, and viral RNA [1].
Such kind of receptors are collectively named pattern recognition receptors (PRRs), and can
be grouped into structurally diverse classes according to the protein domains involved in path-
ogen recognition (e.g., C-type lectin domains or leucine-rich repeats) [1,2].
This is well exemplified by the Scavenger Receptors (SRs), a large group of cell surface and
soluble protein receptors that are structurally diverse and participate in a wide range of biolog-
ical functions (endocytosis, phagocytosis, adhesion, and signaling) following binding to multi-
ple non-self or altered-self ligands [3,4]. Some SR (namely SR-A and SR-I) are characterized
by the presence of one or multiple repeats of an ancient and highly conserved cysteine-rich
protein domain named SRCR (for scavenger receptor cysteine-rich) and constitute a super-
family (SRCR-SF) comprising more than 30 different cell-surface and/or secreted proteins
present from lower invertebrates to mammals, as well as in algae and plants [5,6]. Despite the
high degree of structural conservation among SRCR-SF members, a common single unifying
function has not been reported. However, a steadily growing bunch of SRCR-SF members is
known to interact with diverse microbial (bacterial, fungal, parasitic and/or viral) structures
[6,7]. This is the case of the functionally and structurally highly homologous lymphocyte SR-I
receptors CD5 and CD6. These two receptors are encoded by contiguous genes thought to
derive from duplication of a common ancestral gene and are mainly expressed on all T cells,
and a minor subset of B cells (B1a cells) [6]. The extracellular regions of both receptors are
exclusively composed of 3 consecutive SRCR domains showing extensive sequence identity
[8]. Their diverging cytoplasmic tails are devoid of intrinsic catalytic activity but both display
several structural motifs compatible with a signaling transduction function [6]. Importantly,
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CD5 and CD6 are physically associated with the clonotypic antigen-specific receptor complex
present on T and B1a cells (TCR and BCR, respectively) [9,10] and are involved in the fine tun-
ing of the activation and differentiation signals generated by such relevant receptors through
still incompletely understood and complex signaling pathways [11]. In addition to their immu-
nomodulatory properties, CD5 and CD6 also exhibit PRRs activities. Available data indicate
that soluble and membrane-bound forms of CD6, but not of CD5, bind to Gram-negative and
Gram-positive bacteria through recognition of LPS and LTA, respectively [12,13]. In contrast,
soluble and membrane-bound forms of CD5, but not of CD6, recognize and bind to sapro-
phytic and pathogenic fungal species through β-glucans [14]. More recently, CD5 has been
reported as a key receptor for human hepatitis C virus (HCV) entry into T lymphocytes [15],
and preliminary observations indicate that CD6 may interact with human immunodeficiency
virus 1 (HIV-1) [16]. It remains to be explored, however, whether the broad PRR activity
exhibited by CD5 and CD6 also includes other groups of pathogen besides bacteria, fungi and
viruses.
Helminths -a diverse group of metazoan parasites able to produce long-lasting infections in
immunocompetent hosts- currently affect one third of the world population [17]. Helminthia-
ses are usually chronic infections due to the pathogens’ ability to adapt to the defense mecha-
nisms triggered by infected hosts. Therefore, in most cases host immune responses are
ineffective in parasite elimination, and are often associated with polarized and stereotyped
Th2-type responses, with rare to no levels of Th1-type components [18]. In most helminthia-
ses, such an early response bias does not associate with protective immunity [18–20], and
therefore identification of innate receptors able to recognize and respond to parasite-derived
components during early infection stages is highly relevant.
Among helminthiases, cystic echinococcosis (CE) -formerly known as hydatidosis- is a zoo-
notic disease caused by the larval stage of the cestode Echinococcus granulosus sensu lato (s.l.),
which shows a cosmopolitan distribution with high prevalence worldwide [21–23]. E. granulo-
sus s.l. is composed of numerous variants initially called genotypes/strains (G1-G10), which
nowadays are recognized as new species: E. granulosus sensu stricto (s.s.) (G1/G2/G3), E. equi-
nus (G4), E. ortleppi (G5), E. canadensis (G6/G7/G8/G10) and E. felidis (‘lion strain’). Among
them, the G1 genotype of E. granulosus s.s. is the most frequently found worldwide in livestock
and humans [24]. Primary CE occurs in intermediate hosts (domestic and wild ungulates; acci-
dentally humans) via ingestion of eggs containing oncospheres, which later develop into meta-
cestodes -or hydatid cysts- mainly in the liver and lungs of the infected host. Secondary CE
occurs after protoscolex (PSC) spillage from a fertile hydatid cyst within an infected intermedi-
ate host. This kind of CE derives from PSC developmental plasticity, which allows them to
develop either into new cysts within intermediate hosts or into adult worms if ingested by a
definitive host (usually dogs) [25]. Human secondary CE is an important medical problem
associated with the surgical removal of primary cysts. In fact, although actual percentages of
secondary CE cases post-surgery are debatable, recent studies have reported rates of 10–35%
depending mainly on the type of surgery, the geographical location, and the follow-up time
[26–28].
The murine model of secondary CE (inoculation of viable PSC into mice) has been widely
used to study both the basic aspects of E. granulosus s.l. immunobiology [29–35], and the new
chemotherapeutics or therapeutical protocols [36–38], novel vaccine candidates [39–41], and
diagnostic or follow-up tools [42–44]. In this model, secondary CE can be divided into two
stages: an early pre-encystment stage (until day 20–30 post-inoculation) with PSC developing
into hydatid cysts [45], and a late or post-encystment stage in which differentiated cysts grow
and eventually become fertile cysts [46]. Such a sequential developmental process is associated
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with a strong local control of inflammation during the initial phase of PSC differentiation into
hydatid cysts [32,47].
The present report extends PRRs activities of both CD5 and CD6 receptors to helminth par-
asites, using E. granulosus s.l. as a case study. The data we provide indicate that ectodomains
from both receptors recognize specific parasite components present in the tegument of PSC.
Additionally, the prophylactic potential of CD5 and CD6 ectodomains infusion is shown using
the murine model of secondary CE.
Materials and methods
Ethics statement
Experimental animal procedures were performed in compliance with the Spanish Animal
Experimentation Ethics Committee of Universitat de Barcelona School of Medicine, and the
Uruguayan Comisio´n Honoraria de Experimentacio´n Animal (Universidad de la Repu´blica)
according to the Canadian Guidelines on Animals Care and the National Uruguayan Legisla-
tion No.18.611. Protocols were approved by Comite´ de E´tica en el Uso de Animales (Facultad
de Quı´mica—Universidad de la Repu´blica) and were given the Protocol Approval Number
101900-000361-16 (www.expe.edu.uy).
Mice
Wild-type Balb/c and C57BL/6N mice (8–12 weeks old female) were obtained from DILA-
VE-MGAP (Uruguay) or Charles River (France), and housed under specific pathogen-free
(for in vitro studies) or conventional (for experimental infections) conditions at the animal
facilities of Instituto de Higiene (Universidad de la Repu´blica, Uruguay) and of Universitat de
Barcelona School of Medicine (Spain). CD5-deficient (CD5-/-) (provided by C. Raman, Uni-
versity of Alabama, Birmingham, AL) [48] and CD6-deficient (CD6-/-) mice [49] on C57BL/6
background were maintained at the animal facilities of the Universitat de Barcelona School of
Medicine (Spain) under specific pathogen-free conditions.
Parasites and tegumental antigens isolation
For tegumental antigens extraction, E. granulosus s.l. PSC were obtained by aseptic puncture
of fertile bovine hydatid cysts from Uruguayan abattoirs, washed several times with phosphate
buffered saline (PBS) pH 7.2 containing gentamicin (40 μg/mL), and their viability assessed
[29]. Tegumental proteins were extracted from PSC (viability�80%) using an extracting solu-
tion consisting of PBS plus 1% (w/v) MEGA-10, 5 mM EDTA, and 2 mM PMSF [39]. Briefly,
125,000 viable PSC/mL of extracting solution were incubated for 2 h at RT with gentle shaking.
Then, PSC were allowed to settle down and the supernatant was removed and extensively dia-
lyzed against PBS through a cellulose membrane (MW cut-off: 12,000 Da). Protein content of
the obtained antigens (termed PSEx) was assessed using BCA Protein Assay Reagent (Pierce).
PSEx were stored at -20˚C until used. Treated PSC were washed thrice with PBS, and their
physical integrity was confirmed by observation under a light microscope.
For experimental infections, E. granulosus s.s. PSC were obtained by aseptic puncture of fer-
tile bovine or ovine hydatid cysts provided by Uruguayan abattoirs and Dr. Rau´l Manzano-
Roma´n (IRNASA-CSIC, Salamanca, Spain), respectively. In both cases -Spanish as well as
Uruguayan PSC- only parasite batches with�95% viability were used for experimental infec-
tions, and E. granulosus s.s. genotype was confirmed to belong to the G1 strain by sequencing a
fragment of the gene coding for mitochondrial cytochrome c oxidase subunit 1 (CO1), as pre-
viously described [50].
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Expression, purification, and biotinylation of recombinant proteins
Production of purified recombinant soluble proteins encompassing the whole ectodomains of
human CD5 (rshCD5; from R25 to D345) and CD6 (rshCD6; from D25 to R397) receptors (in
PBS with 10% glycerol, pH 7.4) was performed based on previously reported methods [51] but
using SURE CHO-M Cell line clones from the Selexis SURE-technology Platform (Geneva,
Switzerland) and subjecting serum-free supernatants to size exclusion chromatography proto-
cols developed at PX’Therapeutics (Grenoble, France). Bovine serum albumin (BSA) was from
Sigma-Aldrich. Proteins were biotinylated with EZ-Link PEO-maleimide-activated biotin
(Pierce) following the manufacturer’s instructions.
PSC binding assays
Binding of biotin-labelled recombinant proteins to PSC was assessed according to [51] with
slight modifications. Briefly, 5,000 PSC (viability�90%) were incubated in 600 μL of biotiny-
lated rshCD5, rshCD6 or BSA protein solutions (20 μg/mL) in binding buffer (veronal buffer
saline plus 5 mM CaCl2). After 1 h of incubation at RT with gentle orbital rotation, PSC were
pelleted and washed thrice with binding buffer, and 125 μL of each solution was stored for fur-
ther analyses. A new aliquot of 5,000 PSC was added to the remaining solutions and the same
procedure was performed. Sequential incubations were performed with four PSC aliquots.
Then, PSC pellets and 25 μL of stored supernatants (from the original solution and the last
incubation), were mixed with SDS-PAGE reducing sample buffer and heat-denatured during
10 min at 100˚C. Biotin-labelled proteins were developed by Western blotting (see below) fol-
lowing sample resolution in 12% SDS-PAGE and electro-transfer to PVDF membranes (Bio-
Rad).
ELISA binding assays
The binding ability of rshCD5 and rshCD6 proteins to PSC tegumental antigens was assessed
by using 96-well microtiter plates (Nunc, Roskilde, Denmark) coated ON at 4˚C with 100 μL/
well of PSEx in PBS (10 μg/mL), and further blocked for 1 h at RT with 200 μL/well of PBS
containing 1% (w/v) BSA. Increasing concentrations (0–40 μg/mL) of biotinylated rshCD5,
rshCD6 or BSA (100 μL/well) were then added to the wells and incubated ON at 4˚C. Bound
protein was detected by the addition of 100 μL/well HRP-labelled streptavidin (1:5,000—
Sigma) for 1 h at 37˚C. Between every incubation step, unbound proteins were washed out
thrice with PBS containing 0.05% (v/v) Tween-20. Enzymatic activity was developed at RT by
adding 100 μL/well of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate (Sigma). After stopping
the reaction with H2SO4 0.5 M (50μL/well), absorbance values were read at 450 nm.
To assess whether antigens recognized by rshCD5 and rshCD6 within PSEx were carbohy-
drates, a similar ELISA was performed including a step of PSEx oxidation with NaIO4 [33].
Briefly, PSEx-coated and BSA-blocked plates were incubated during 1 h with 20 mM NaIO4 in
50 mM acetate buffer pH 4.5 (200 μL/well) at RT. After three washings with acetate buffer,
treated-wells were incubated for 30 min with 50 mM NaBH4 in PBS (250 μL/well), and 100 μL/
well of biotin-labelled rshCD5 (20 μg/mL) or rshCD6 (10 μg/mL) was added to treated and
untreated wells. The remaining ELISA protocol was performed as described above. Binding to
NaIO4-resistant antigens was assessed as the percentage of absorbance values in treated wells
respect to untreated wells.
ELISA competition was performed to explore potential overlapping between rshCD5 and
rshCD6 for binding to PSEx. Briefly, PSEx-coated and BSA-blocked plates were incubated ON
at 4˚C with 100 μL/well of either a mixture made of a fixed amount of biotin-labelled rshCD5
(20 μg/mL) or rshCD6 (10 μg/mL) and increasing concentrations of unlabeled rshCD6 (0–
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40 μg/mL) or rshCD5 (0–20 μg/mL), respectively. After washing out unbound proteins, the
remaining ELISA protocol was performed as described above. Ligand overlapping was
assessed as the percentage of absorbance values in competed wells respect to non-competed
wells (0 μg/mL of unlabeled protein).
Two-dimension (2D) SDS-PAGE analyses
Analysis of PSEx by 2D SDS-PAGE was performed following standard protocols. Briefly,
300 μg of PSEx antigens were first precipitated by ON incubation at -20˚C in 300 μL ice-cold
acetone containing 20% of trichloracetic acid (TCA) and 0.07% dithiothreitol (DTT) to
remove insoluble proteins and lipids. After centrifugation for 15 min at 10,000g and 4˚C, the
supernatant was discarded and 300 μL of ice-cold acetone containing 20% dimethyl sulfoxide
(DMSO) and 0.07% DTT were added and incubated for 1 h at -20˚C. Then, samples were cen-
trifuged for 15 min at 10,000g and 4˚C, the supernatants discarded, and 300 μL ice-cold ace-
tone containing 0.07% DTT were added. This step was repeated twice. Finally, the pellet was
lyophilized, rehydrated in immobilized pH gradient (IPG) buffer (GE Healthcare) and frozen
at -80˚C for 24 h to improve solubilization. For the first dimension, 7 cm linear pH gradient
(pH 3–10) Immobilie DryStrips (GE Healthcare) were re-hydrated with the sample and run on
an IPGphore isoelectric focusing system (9.5 h run and a total of 35.5 KV/h), and stored at
-80˚C until use. Strips were then soaked for 15 min in equilibration buffer (50 mM Tris-Cl pH
8.8, 6 M urea, 30% glycerol, 2% SDS, and traces of bromphenol blue) containing 10 mg/mL
DTT, further soaked for 15 min in equilibration buffer containing 25 mg/mL iodoacetamide,
and sealed to 10% acrylamide gels using 0.5% agarose in standard Tris-glycine electrophoresis
buffer. Second dimension SDS-PAGE was run at 50 V for the first 15 min and then raised to
150 V until ending. Finally, replicates of 2D SDS-PAGE gels were subjected either to mass-
spec compatible silver nitrate staining or to electro-transference to PVDF membranes (Bio-
Rad) for Western blotting.
Western blotting
Electro-transferred PVDF membranes either from PSC binding assays or from PSEx 2D
SDS-PAGE were blocked with 1% (w/v, in PBS) BSA for 2 h at RT. Membranes from PSEx 2D
SDS-PAGE were additionally incubated ON at 4˚C with solutions of biotin-labeled rshCD5 or
rshCD6 (15 μg/mL). All membranes were then incubated for 1 h at 37˚C in a PBS solution of
0.1% (w/v) BSA and 0.05% (v/v) Tween-20 containing HRP-streptavidin (1:5,000—Sigma).
Finally, membranes were extensively washed with PBS plus 0.05% (v/v) Tween-20, and blots
were developed by chemo-luminescence (SuperSignal West Pico Substrate, ThermoScientific)
in a G-Box equipment (Syngene).
Proteomic analyses
Clean spots observed in PSEx 2D SDS-PAGE transferred PVDF membranes Western blotted
with biotinylated rshCD5 and rshCD6 were manually back-mapped on gels for mass spec-
trometry identification at the Proteomic Facility of Pasteur Institut (Montevideo). Briefly,
spots were excised, faded and tryptic digestions were performed using sequencing-grade mod-
ified trypsin (Promega). After gel extraction into 60% acetonitrile containing 0.1% TFA, the
excess of acetonitrile was removed by speed vacuum. Peptide samples were then combined
with an equal volume of matrix, spotted onto a MALDI sample plate, and allowed to dry at RT.
Mass spectra were acquired on a 4800 MALDI TOF/TOF Mass Analyzer (Abi Sciex) operating
in the positive ion reflector mode. Protein identifications were performed using an in-house
Mascot v.2.3 search engine by searching a custom database that includes the full proteome of
CD5 and CD6 and secondary cystic echinococcosis
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E. granulosus s.l. and E. multilocularis, composed of 20,787 sequences (10,310,548 residues)
obtained from the Sanger Helminth Database. Additionally, every mass spectrum was also
analyzed using NCBI database to discard possible host related proteins. The search criteria
used were cystein carbamidomethylation and methionine oxidation as variable modification,
and mass deviation <200 ppm with peptide fragment tolerance of 0.45 Da. Scores>56 were
considered significant (P<0.05).
Flow cytometry studies
Assessment of fluorescein isothiocyanate (FITC)-labelled PSEx binding to membrane-bound
CD5 or CD6 was performed by flow cytometry analyses of parental 2G5 cells (a Jurkat cell
derivative selected for deficient CD5 and CD6 expression [52]) and stable 2G5-transfectants
expressing wild-type human CD5 (2G5-CD5.wt) or CD6 (2G5-CD6.wt) [10]. FITC labeling of
PSEx was done as previously reported [53] using fluorescein isothyiocyanate (Sigma). Briefly,
1 mg of PSEx was dialyzed against 100 mM NaHCO3 buffer pH 9, and then 500 μg of FITC
(Sigma) in DMSO were added. After 8 h of vigorous shaking in the dark, the mixture was
extensively dialyzed against PBS and stored at 4˚C until use. Binding assays were performed by
incubating 2x105 2G5, 2G5-CD5.wt and 2G5-CD6.wt cells with increasing amounts of FITC-
labelled PSEx in blocking buffer (PBS plus 10% human AB serum, 2% FCS and 0.02% NaN3)
for 30 min at 4˚C. Then, cells were washed thrice with washing buffer (PBS plus 2% FCS and
0.02% NaN3) and analyzed on a FACSCalibur flow cytometer using CellQuest software (Bec-
ton Dickinson). Additionally, competition assays were performed in a similar way, but incu-
bating cells with a fixed amount (10 μg) of FITC-labelled PSEx in the presence of increasing
amounts (5–20 μg) of unlabeled rshCD5, rshCD6 or BSA.
Cell cultures
The influence of the interaction between PSC tegumental antigens and CD5/CD6 on the
PSEx-induced cytokine profile was first assessed by cell cultures of spleen and peritoneal cells
from naïve CD5-/- [48], CD6-/- [49] and their corresponding C57BL/6 wild-type littermates in
the presence of increasing concentrations of PSEx (0–40 μg/mL). Secondly, peritoneal cells
from naïve C57BL/6 wild-type mice were stimulated with a fixed concentration of PSEx
(20 μg/mL) in the presence of increasing amounts of rshCD5, rshCD6 or BSA (0–40 μg/mL).
Spleen cells were obtained by mechanically disrupting spleens with a syringe plunger through
a cell strainer. Harvesting of peritoneal cells was done by repeated washings (4 times with 2
mL/washing) of peritoneal cavities with cold PBS plus 2% FCS. Both procedures were per-
formed under sterile conditions. Cell pellets -either from spleen or peritoneal cells- were
treated with red blood cell lysing buffer (Sigma) following manufacturer’s instructions, and
then suspended in complete culture medium (RPMI 1640 plus 10% FCS, 50 μM 2-mercap-
toethanol, 100 μg/mL streptomycin and 100 U/mL penicillin, all from Sigma) and counted.
Cells were seeded in 96-wells U-bottom plates at 2x105 cells/well in 200μL of complete culture
medium and then incubated for 72 h at 37˚C in a 5% CO2 atmosphere. Stimulation of cells
with 10 μg/mL LPS (Sigma) was used as a positive control.
Cytokines measurement by ELISA
Mouse cytokine levels in culture supernatants were determined by commercially available
ELISA kits following the manufacturer’s instructions. The IL-17A ELISA kit was from R&D
Systems. The IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, TNF-α and IFN-γ BD OptEIA--
Mouse ELISA Sets were from BD Biosciences Pharmigen.
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Murine model of secondary CE
To assess whether rshCD5 or rshCD6 could modulate CE outcome, secondary infections were
performed in Balb/c mice [33,35]. Mice were administered with rshCD5, rshCD6 or BSA in
200 μL sterile PBS (25 μg, i.p.) one hour before (-1h) and after (+1h) i.p. inoculation of 2,000
PSC (viability�95%) in 200 μL of sterile PBS. Mice were euthanized 14 months post-challenge
and peritoneal cysts were recovered. Groups were compared in terms of (i) frequency of infec-
tion (proportion of mice harboring at least one cyst), (ii) number of developed cyst within
each mouse, and (iii) total mass of cyst within each mouse (cyst wet-weight).
Statistical analyses
Depending on the characteristics of the values, statistical analyses were assessed by either Stu-
dent’s t-test (parametric values), Mann-Whitney U-test (non-parametric values) or Fisher’s
exact test (non-parametric contingencies). Differences were regarded as significant when P
<0.05.
Results
CD5 and CD6 ectodomains bind to different PSC tegumental antigens
In order to determine whether the human CD5 and CD6 ectodomains are able to directly bind
to the surface of viable E. granulosus s.l. PSC, pathogen-binding assays previously used for
exploring their putative interaction with fungal and bacterial cell wall components, respec-
tively, were performed [12,14]. Thus, biotinylated rshCD5 and rshCD6 proteins were sequen-
tially incubated with viable PSC suspensions, and SDS-PAGE and Western blotting of pellets
against streptavidin-HRP further assayed their adsorption to PSC. The results showed that
both rshCD5 and rshCD6 (but not BSA, used as a negative control) bound to viable PSC (Fig
1A), indicating that they possess helminth-parasite binding activity.
Next, it was investigated whether the observed binding of rshCD5 and rshCD6 to viable
PSC involved tegumental components. To that end, increasing concentrations of biotin-
labeled proteins were assayed on ELISA plates coated with the antigenic fraction termed PSEx,
composed of PSC tegumental antigens. Results depicted in Fig 1B show that both, biotinylated
rshCD5 and rshCD6 (but not BSA), interact with structures present in the PSEx fraction in a
dose-dependent manner. Additionally, when assayed the supernatants resulting from sequen-
tial incubations of PSC with biotin-labeled rshCD5 and rshCD6 depicted in Fig 1A, reactivity
against PSEx decreased as the number of incubations increased, in accordance with a sequen-
tial co-precipitation phenomenon (Fig 1C).
Once evidenced the interaction of rshCD5 and rshCD6 with the PSEx fraction, the bio-
chemical characterization of the PSEx components involved was addressed. To that end, an
ELISA-based assay was first performed to determine whether rshCD5 and rshCD6 interactors
were metaperiodate-sensitive (i.e. carbohydrates) or -resistant (i.e. proteins/lipids) com-
pounds. Results depicted in Fig 2A indicate that all rshCD6- and most rshCD5-mediated inter-
actions were metaperiodate-resistant, suggesting they are of protein and/or lipid nature. Then,
in order to assess if the ligand patterns are similar or different for each molecule, we performed
competition experiments in PSEx-coated ELISA plates with a fixed concentration of biotin-
labeled rshCD5 incubated with increasing amounts of unlabeled rshCD6, and vice versa (i.e.
fixed biotin-labeled rshCD6 and increasing amounts of unlabeled rshCD5). The results
obtained indicate that rshCD5 and rshCD6 exhibit little overlapping regarding their PSEx
interactions (Fig 2B). This was further supported by Western blotting the 2D SDS-PAGE
resolved PSEx fraction with biotinylated rshCD5 or rshCD6 and HRP-labeled streptavidin. As
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Fig 1. CD5 and CD6 ectodomains bind PSC tegumental antigens. (A) Biotin-labeled rshCD5, rshCD6 and BSA
protein solutions (20 μg/mL) were sequentially incubated (4 times) with PSC suspensions (5,000 PSC; viability�90%),
and pellets and solutions run on SDS-PAGE and further Western blotted with HRP-streptavidin. Lanes 1 and 2:
protein solutions before (0x) and after 4 sequential incubations with PSC (4x), respectively. Lanes 3 to 7: PSC pellets
after 0x to 4x sequential incubations. (B) ELISA assays showing the binding of increasing amounts of biotinylated
rshCD5, rshCD6 and BSA proteins to PSEx-coated plates. (C) ELISA assays showing the binding of supernatants from
sequential PSC incubations of biotin-labeled rshCD5, rshCD6 and BSA depicted in (A), to PSEx-coated plates. N.D.
not detected. (�) Significant differences (Student’s t-test, P<0.05) respect to 0x results.
https://doi.org/10.1371/journal.pntd.0006891.g001
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illustrated by Fig 2C, rshCD5 and rshCD6 differed regarding their “spot” pattern reactive with
the PSEx fraction. Accordingly, MALDI-TOF/TOF analyses identified parasite thioredoxin
peroxidase as a potential interactor for rshCD5, and parasite peptidyl-prolyl cis-trans isomer-
ase (cyclophilin) and endophilin B1 (antigen P-29) in the case of rshCD6 (Table 1). Summing
up, these results indicate that both rshCD5 and rshCD6 molecules exhibit binding capacity to
Fig 2. Tegumental antigens recognized by rshCD5 and rshCD6 are different. (A) ELISA assays showing binding of rshCD5 and
rshCD6 to PSEx-coated plates undergoing metaperiodate treatment (NaIO4) or not (control). Binding to metaperiodate-resistant
antigens was assessed as the percentage of absorbance values in treated wells respect to untreated wells (triplicates in each case). (B)
Competition binding assays in which binding of a fixed amount of biotinylated rshCD5 (20 μg/mL; left) or rshCD6 (10 μg/mL; right) to
PSEx-coated ELISA were competed with increasing amounts of unlabeled rshCD6 and rshCD5 proteins, respectively. Ligand
overlapping was assessed (in triplicates) as the percentage of absorbance values in competed wells respect to non-competed wells (0 μg/
mL of unlabeled protein). (C) 2D SDS-PAGE resolved PSEx fractions were either silver stained (left) or electro-transferred onto PVDF
membranes for further Western blotting with biotin-labeled rshCD5 (middle) or rshCD6 (right). (�) Significant differences (Student’s t-
test, P<0.05) respect to control (A) or uncompleted (B) wells.
https://doi.org/10.1371/journal.pntd.0006891.g002
Table 1. Potential parasite ligands for rshCD5 and rshCD6 identified by 2D SDS-PAGE and further MALDI-TOF/TOF mass spectrometry analysis.
Receptor Potential ligand UniProtKB identifier MW (Da) IP Length (aa) MASCOT score Sequence coverage (%) Previously identified
rshCD6 Endophilin B1 A0A068WMU2 28,782 5.83 252 245 67 74–76
Peptidyl-prolyl cis-trans
isomerase
P14088 17,343 6.41 162 232 35 73,75,78,79
rshCD5 Thioredoxin peroxidase Q8T6C4 21,392 5.78 193 79 55 73–77
https://doi.org/10.1371/journal.pntd.0006891.t001
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different structures -mainly proteins and/or lipids- present in the tegument of E. granulosus s.l.
PSC, expanding their known spectrum of pathogen recognition.
Binding of membrane-bound CD5 and CD6 to PSC tegumental antigens
Next, it was questioned whether membrane-bound forms of human CD5 and/or CD6 lympho-
cyte receptors also retain their PSEx-binding activity. To that end, binding of FITC-labeled
PSEx to parental 2G5 cells (a Jurkat T cell derivative selected for deficient CD5 and CD6
expression [52]) and to stable 2G5 transfectants expressing wild-type CD5 (2G5-CD5.wt) and
CD6 (2G5-CD6.wt) surface receptors [10] was analyzed by flow cytometry. As shown in Fig
3A, mean fluorescence intensity (MFI) was significantly higher for 2G5-CD5.wt and
2G5-CD6.wt transfectants compared with parental untransfected 2G5 cells. The specificity of
these interactions was confirmed by competition binding experiments, in which binding of a
fixed amount of FITC-labeled PSEx to 2G5-CD5.wt and 2G5-CD6.wt cells was competed in a
dose-dependent manner by unlabeled rshCD5 and rshCD6, respectively (Fig 3B). By contrast,
unlabeled BSA (included as a negative control protein) did not inhibit binding of FITC-PSEx
to 2G5-CD5.wt nor 2G5-CD6.wt (S1 Fig). Taken together, this evidence indicates that cell sur-
face-expressed CD5 and CD6 retain PSEx-binding activity as well.
Modulation of PSEx-induced cytokine production by membrane-bound
and soluble CD5 and CD6 proteins
The influence of cell surface CD5 or CD6 expression on PSEx-induced cytokine production by
spleen and peritoneal cells (PECs) from either naïve CD5-/- or CD6-/- mice, as well as their
respective wild-type controls was first analyzed. To that end, cells were cultured for 72 h in the
presence of increasing amounts of PSEx, and then cytokine production in supernatants was
analyzed by capture ELISA. Spleen cells showed no significant PSEx-induced cytokine produc-
tion over background (S2 Fig), in agreement to previous reports for other PSC-derived anti-
gens [29,30,54]. By contrast, PSEx simulation of PECs resulted only in significant IL-10, TNF-
α and IL-6 cytokine responses. Therefore, our further analyses focused on those cytokines
within supernatants of cultured PECs. Since levels of spontaneous cytokine secretion usually
differed between PECs from knockout and wild type mice (S3 Fig), results were further dis-
played in terms of fold changes for an easier interpretation.
As illustrated by Fig 4A, while no differences were observed regarding IL-10 induction,
PSEx-stimulated PECs from CD5-/- mice underwent significant higher fold-increases for TNF-
α and lower for IL-6 than their wild-type mice counterparts. Regarding CD6 surface expres-
sion, the results depicted in Fig 4B showed that PSEx-stimulation of PECs from CD6-/- mice
underwent significant higher fold-increases for IL-6 but not TNF-α or IL-10 than their wild-
type mice counterparts. On the other hand, LPS-stimulated PECs (included as a positive stim-
ulation control) from CD5-/- and CD6-/- mice exhibited higher fold-increases for IL-10 and
TNF-α and lower fold-increases only for IL-10, respectively, than their wild-type counterparts
(Fig 4A and 4B), suggesting an overall antigen-independent difference in stimulation
threshold.
To exclude possible CD5/CD6-independent alterations in knockout mice, TNF-α, IL-6 and
IL-10 cytokine levels in supernatants of PSEx-stimulated PECs from wild-type C57BL/6 mice
in the presence of increasing amounts of rshCD5 or rshCD6 were also assessed. This strategy
might reduce the interaction of PSEx with membrane-bound CD5 and CD6 through direct
competition with the soluble forms of the receptor recombinant ectodomains. Regarding
PSEx-induced IL-10 secretion, no variations due to rshCD5 addition was observed, while
rshCD6 significantly reduced IL-10 levels (Fig 5A and 5B, top bar charts). On the other hand,
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rshCD5 as well as rshCD6 both modified TNF-α and IL-6 (Fig 5A and 5B, middle and bottom
bar charts) production in response to PSEx, but in opposite ways. Thus, while rshCD5 addition
increased PSEx-induced TNF-α and IL-6 production by wild-type PECs, rshCD6 decreased
the secretion levels of both cytokines. BSA addition (included as a negative control) did not
affect PSEx-stimulated cytokine responses (Fig 5A and 5B).
Taken together this set of results indicates that either the absence of cell surface CD5 and
CD6 receptors or the presence of both receptors in soluble form modulate the cytokine
responses induced by tegumental antigens from E. granulosus s.l. PSC in different ways. Inter-
estingly, the blockade of PSEx components by rshCD5 seems to up-regulate pro-inflammatory
cytokine responses (i.e. increasing TNF-α and IL-6 secretion, without affecting IL-10 produc-
tion levels), while blockade through rshCD6 seems to overall down-regulate the PSEx-induced
cytokine response (i.e. decreasing the production of the three induced cytokines).
Fig 3. Native membrane-bound CD5 and CD6 receptors retain PSEx-binding capacity. (A) Flow cytometry analyses of 2G5, 2G5-CD5.wt or
2G5-CD6.wt cells stained with increasing amounts of FITC-labeled PSEx. Represented are the mean fluorescence intensity (MFI) values (left) and a
representative flow cytometry histogram from each case (right). (B) Competition binding experiments in which 2G5-CD5.wt or 2G5-CD6.wt cells were
stained with a fixed suboptimal amount of FITC-labeled PSEx in the presence or absence of different amounts of unlabeled rshCD5 or rshCD6 proteins.
Both experiments were performed in quadruplicates and results are shown as mean +/- SD. (�) Significant differences (Student’s t-test, P<0.05) respect
to 2G5 cells (A) or cells with 0 μg of competing proteins (B).
https://doi.org/10.1371/journal.pntd.0006891.g003
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Infusion of rshCD5 or rshCD6 protects mice from secondary CE
In light of the observed modulation by rshCD5 and rshCD6 of PSEx-induced cytokine
responses in PECs from wild-type mice, it was further assessed whether rshCD5 or rshCD6
administration would modify the infection outcome in a mouse model of secondary CE. To
that end, rshCD5 and rshCD6 (25 μg/mouse) were i.p. infused 1 h before and after i.p. inocula-
tion of viable PSC (2,000/mouse) into Balb/c mice, a highly susceptible mouse strain to sec-
ondary CE [33]. The i.p. route for rshCD5/rshCD6 administration was chosen because the
peritoneal cavity is the natural anatomical site for infection establishment and hydatid cyst
development in this infection model. At 14 months post-infection, mice were euthanized for
infection inspection, and the peritoneal hydatid cysts within each mouse were counted and
weighted. As illustrated by Fig 6A, rshCD5 infusion exhibited a remarkable prophylactic
Fig 4. PSEx-induced cytokine production by naïve cells from CD5-/- and CD6-/- mice. (A) Peritoneal cells from naïve CD5-/- (n = 3, pooled) and
wild-type (n = 3, pooled) control mice, were cultured for 72 h in the presence of increasing amounts of PSEx, and then cytokine production in
supernatants was analyzed by capture ELISA. Results are displayed as fold increases respect to unstimulated cells (mean +/- SEM). (B) Same as in (A)
for CD6-/- and wild-type control mice. Both experiments were performed in quadruplicates. (�) Significant differences (Student’s t-test, P<0.05) respect
to unstimulated cells.
https://doi.org/10.1371/journal.pntd.0006891.g004
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Fig 5. Modulation of PSEx-induced cytokine production by rshCD5 or rshCD6. (A) Peritoneal cells from naïve wild-type C57BL/
6 mice (n = 3, pooled) were stimulated with a fixed concentration of PSEx (20 μg/mL) for 72 h in the presence of the indicated
amounts of rshCD5, BSA or LPS. Results are displayed as cytokine concentration in supernatants (mean +/- SEM). (B) Same as in
(A) using the indicated amounts of rshCD6 instead of rshCD5. Both experiments were performed in quadruplicates. (�) Significant
differences (Student’s t-test, P<0.05) respect to cells stimulated only with PSEx.
https://doi.org/10.1371/journal.pntd.0006891.g005
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potential against secondary CE, since it significantly reduced the proportion of infected indi-
viduals, as well as the number of hydatid cysts per mouse (Fig 6B), and the total wet weight of
hydatid cysts per mouse (Fig 6C). On the other hand, rshCD6 infusion also exhibited some
degree of prophylactic potential in secondary CE, since a trend towards reduction in the pro-
portion of infected mice (Fig 6A) and the number of hydatid cysts per mouse (Fig 6B) was
observed. Infusion of equivalent doses of BSA did not affect any parasitological parameter of
infection outcome (Fig 6A–6C).
Finally, our results showed that rshCD5 -and to a lesser extent rshCD6 as well- exhibit pro-
phylactic potential in the murine model of secondary CE.
Discussion
Effective mammalian immune responses rely on the early recognition of pathogen-derived
components by innate immunity related receptors, otherwise named PRRs. Data on key early
steps of helminth parasitic infections is scarce. Functional approaches suggest the involvement
of different TLRs (namely TLR4, TLR3, and TLR2) [55–59], and SRs in the recognition of hel-
minth components. Current mammalian SRs include 10 different classes (SR-A to SR-L;
excluding SR-C only present in Drosophila melanogaster), being class E (SR-E) the most
important group in helminth-derived antigens recognition, including Dectin-2 [60], Mannose
Receptor/CD206 [61–63], CLEC4F/CLECSF13 [64], and DC-SIGN/CD209a [65]. Our work
expands the group of SRs interacting with helminth pathogens to CD5 and CD6, two lym-
phoid members of the class I (SR-I).
SR-I ectodomains harbor several tandem repeats of the SRCR protein module. In addition
to CD5 and CD6, SR-I members include CD163A/M130, CD163B/M160, SCART1, SCART2
and WC1 [3,4]. Macrophages and lymphocyte subsets expressing CD163 or WC1, respectively,
play a role against certain parasite infections (e.g. Theileria parva [66], Leishmania braziliensis
Fig 6. Infusion rshCD5 or rshCD6 protects mice from secondary CE. The anti-parasite prophylactic potential of rshCD5 or rshCD6 was assessed in
the murine model of secondary CE by infusing PBS, rshCD5, rshCD6 or BSA (25μg/dose/mouse, i.p.) 1 h before and 1 h after i.p. inoculation of 2,000
highly viable PSC/mouse into Balb/c mice (n = 6–8 mice per experimental group). At 14 months post infection, mice were euthanized, and the
peritoneal hydatid cysts within each mouse were counted and weighted. Results are displayed as percentage of infected mice (A), number (mean +/-
SEM) of hydatid cysts per mouse (B), and total wet weight (mean +/- SEM) of hydatid cysts per mouse (C). The experiment was performed twice. (�)
Significant differences (P<0.05) respect to the PBS group were assessed by either Fisher’s exact test (A) or Mann-Whitney U-test (B and C).
https://doi.org/10.1371/journal.pntd.0006891.g006
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[67], Trypanosoma vivax [68], or Neospora caninum [69]), but no direct interaction with para-
site helminth structures has been previously reported.
A single C-terminal SRCR domain characterizes class A SRs (SR-A), including the SR-AI,
MARCO, and SCARA5 receptors [3]. While some evidence supports the involvement of
SR-AI and MARCO in parasite infection (Schistosoma japonicum and Leishmania major,
respectively) [70,71], the ability of SR-AI to directly recognize helminth components has only
been shown for Heligmosomoides polygyrus calreticulin [72]. The present study shows that
CD5 and CD6 should be added to the list of SRs able to sense helminth components. Soluble
CD5 and CD6 physically bind to different components within the tegument of E. granulosus s.
l. PSC, modulate their induced cytokine profiles in naïve peritoneal cells, and protect mice
from secondary CE.
Tegumental components are crucial for helminth physiology (i.e. nutrients up-take and
waste disposal) and for their ability to modulate immune responses leading to chronic parasite
establishments. They are the first parasite structures recognized by soluble and/or membrane-
bound host receptors. Therefore, it is highly relevant to identify which receptors hold the abil-
ity to recognize them and, if possible, the involved parasite structures. We determine that
human CD5 and CD6 ectodomains bind to the surface of viable PSC (Fig 1A). More specifi-
cally, CD5 and CD6 interact with components of an antigenic fraction termed PSEx, which is
mainly composed of tegumental antigens from PSC (Fig 1B). Such PSEx components are
metaperiodate-resistant compounds, indicating their protein and/or lipid nature (Fig 2A).
Additionally, bound components differed depending on the receptor analyzed (Fig 2B). 2D
SDS-PAGE and MALDI-TOF/TOF analyses of the PSEx fraction provides a differentiated spot
pattern (Fig 2B and 2C), and a distinctive set of potential parasite ligands for each receptor:
thioredoxin peroxidase for CD5, and peptidyl-prolyl cis-trans isomerase (cyclophilin) as well
as endophilin B1 (P-29 antigen) for CD6 (Table 1). These results show that CD5 and CD6
ligands within PSEx do not fully overlap.
The CD5 and CD6 ligands besides being present in the PSEx fraction, have been found in
other sources of E. granulosus s.l. antigens. Thioredoxin peroxidase has been detected in differ-
ent PSC antigen sources [73–75], in hydatid fluid [76], in adult worms [74], and in extracellu-
lar vesicles obtained from fertile cysts [77]. Endophilin B1 (P-29 antigen) has been detected in
somatic antigens of PSC and adult worms [74], in nuclear and cytosolic extracts of PSC [75],
and in hydatid fluid [76]. Finally, peptidyl-prolyl cis-trans isomerase (cyclophilin), has been
detected in PSC excretion/secretion products [73], in nuclear and cytosolic extracts of PSC
[75], and in hydatid fluid [78,79]. Implying that CD5/CD6 parasite sensing would span the dif-
ferent stages of E. granulosus s.l. life cycle and not be limited to tegumental structures from
PSC.
PSEx interaction with CD5 and CD6 is also extendable to their membrane-bound forms, as
demonstrated by binding (and competition binding) experiments of FITC-labelled PSEx to
parental and stably CD5- and CD6-transfected 2G5 cells -a Jurkat cell derivative deficient for
surface CD5 and CD6 expression (Fig 3A and 3B). The basal interaction observed between
PSEx and parental 2G5 cells suggests other cell surface receptors in parasite interaction (Fig
3A). Jurkat cells (a human CD4+ T cell lymphoma line) have been shown to express most
TLRs [80], and 2G5 cell line in particular has been previously checked for surface expression
of TLR2 and TLR4 [12,14]. Therefore, membrane-expressed CD5 and CD6 receptors specifi-
cally interact with PSEx components, even if other surface molecules may concomitantly act as
PSEx-binding receptors.
Specific recognition of parasite structures by membrane-bound CD5 and CD6 may have
relevant functional consequences, since both receptors induce intracellular signalling (namely
MAPK cascade activation) when ligated by PAMPs [12,14]. PECs harbor CD5 and/or CD6
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expressing immune cells involved in helminth infection protection. They include all T cells
(comprising Tγδ and iNKT) and B1a cells as well as a macrophage subset [81]. Interestingly,
CD5+ B1a cells are an important source of polyreactive natural IgM antibodies [82] and of IL-
10 [83]. Thus, CD5- and CD6-mediated signalling by immune PECs may contribute to rele-
vant biological effects, like modulation of cytokine production and release. Accordingly, PSEx-
induced stimulation of PECs from CD5- and CD6-deficient mice resulted in different cytokine
responses compared with their wild type controls (Fig 4). Interestingly, such differences were
also observed following LPS-stimulation, suggesting an overall difference in stimulation
thresholds (Fig 4). Indeed, data from knockout mice have shown the involvement of mem-
brane-bound CD5 and CD6 in the fine-tuning of T (and likely B1a) cell subset responses
[11,84]. Thus, the possibility that differences observed in PSEx-induced cytokine production
by CD5- and CD6-deficient mice could be due to effects beyond direct recognition of parasite
ligands by membrane-bound CD5 or CD6, was further excluded by similar PSEx stimulation
studies in wild type mice in the presence of increasing amounts of soluble CD5 or CD6. The
results showed that rshCD5 up-regulated PSEx-induced pro-inflammatory cytokine responses
(i.e. increased TNF-α and IL-6 secretion, without altering IL-10 production rates) (Fig 5A),
while rshCD6 down regulated the overall (TNF-α, IL-6 and IL-10) cytokine response (Fig 5B).
Such findings are highly relevant either in a basic immunological sense, as well as from a
potential prophylactic point of view.
Cytokine profiles are relevant for host susceptibility/resistance to E. granulosus s.l. infection.
Thus, pro-inflammatory responses have been associated with host protection either in experi-
mental infection models [30,34,85,86] as well as in human patients [87–91], being nitric oxide-
mediated mechanisms involved in such protection [89–92]. Our results indicate that CD5 or
CD6 binding to tegumental antigens from PSC contribute to cytokine induction associated
with parasite establishments, and is not optimal for parasite killing and clearance. From a pro-
phylactic point of view, in vivo infusion of rshCD5 or rshCD6 during the early stages of para-
site establishment may be a useful strategy for immunomodulating the host into an anti-
parasite state. Accordingly, the assessment of in vivo administration of rshCD5 or rshCD6 in a
mouse model of secondary CE resulted in a remarkable prophylactic potential of the former,
since it reduced not only the proportion of infected mice, but also the number of developed
hydatid cysts per mouse and their parasite loads (Fig 6). A trend towards reduction in the pro-
portion of infected individuals and the number of developed hydatid cysts was observed in
rshCD6 infusion (Fig 6). The prophylactic potential of rshCD5 may correspond to pro-inflam-
matory cytokine (TNF-α and IL-6) upregulation (Fig 5A), while CD6 lesser efficiency parallels
down-modulating cytokine production, especially IL-10 (Fig 5B), a cytokine usually associated
with increased susceptibility to E. granulosus s.l. infection [31,34,90]. In this sense, our preclin-
ical results might be useful for designing/proposing a novel strategy to reduce secondary infec-
tion rates in CE patients. For example, once a hydatid cyst is surgically removed, a
concomitant intraperitoneal infusion of rshCD5 -or rshCD6- would help in preventing
remaining PSC to develop into new hydatid cysts.
Interestingly, besides modulating cytokine production, the potential ligands identified for
both CD5 and CD6 receptors are highly relevant for E. granulosus s.l. physiology. Thioredoxin
peroxidase is a key enzyme for reactive oxygen species detoxification in E. granulosus s.l.
[93,94]; while peptidyl-prolyl cis-trans isomerase (cyclophilin) has been associated with para-
site sensitivity to lethal effects of cyclosporine A [95], and endophilin B1 (P-29 antigen)
revealed significant protective activity against secondary CE in mice [96], as well as against pri-
mary infection in sheep [97], when used as a vaccine antigen. Therefore, the binding of such
parasite components by rshCD5 or rshCD6 may also contribute to a better host parasite
control.
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In conclusion, we provide the first evidence for direct recognition of tegumental PSC struc-
tures from E. granulosus s.l. by SR-I CD5 and CD6, in addition to bacterial, fungal, and/or
viral components binding. Moreover, we prove the prophylactic potential of soluble CD5 (and
CD6) infusion in the mouse model of secondary CE. In this sense, such a prophylactic poten-
tial could be ascribed either to: (i) a cytokine-modulating activity through the competition
with the interaction between tegumental antigens and host membrane-bound forms of CD5/
CD6; (ii) the blockade of key tegumental components highly relevant for PSC physiology; or
(iii) a mixture of both situations finally contributing to a better parasite control. Additionally,
although CE has a cosmopolitan distribution and represents a major public health problem in
regions of South America, Mediterranean, Central and Western Asia, and East Africa [98], our
PSC experimental infections were performed with E. granulosus s.s. G1 genotype, which shows
the highest cosmopolitan distribution and is responsible for most human CE cases worldwide
[24,99]. Further work is required to ascertain CD5 and CD6 prophylactic potential in other
helminth-driven pathologies and to explore if additional SRCR-SF members share such
interactions.
Supporting information
S1 Fig. Native membrane-bound CD5 and CD6 receptors retain PSEx-binding capacity.
Competition binding experiments in which 2G5-CD5.wt or 2G5-CD6.wt cells were stained
with a fixed suboptimal amount of FITC-labeled PSEx in the presence or absence of different
amounts of unlabeled BSA. Both experiments were performed in quadruplicates and results
are shown as mean +/- SD. (�) Significant differences (Student’s t-test, P<0.05) respect to cells
with 0 μg of competing BSA.
(TIF)
S2 Fig. PSEx-induced cytokine production by naïve spleen cells from CD5-/-, CD6-/- and
their WT littermates. Spleen cells from naïve CD5-/- or CD6-/- (n = 3, pooled) and their
respective wild-type (n = 3, pooled) control mice, were cultured for 72 h in the presence of
increasing amounts of PSEx or LPS (positive control), and then cytokine production in super-
natants was analyzed by capture ELISA. Cytokine concentrations are displayed as mean +/-
SD of quadruplicates. ND (Not Detected).
(TIF)
S3 Fig. Basal cytokine production by peritoneal cells from CD5-/-, CD6-/- and their respec-
tive WT mice. Peritoneal cells from naïve CD5-/-, CD6-/- and their respective wild-type control
mice (in all cases: n = 3, pooled), were cultured for 72 h in complete culture medium alone,
and then IL-6, IL-10 and TNF-α production in supernatants was analyzed by capture ELISA.
Cytokine concentrations are displayed as mean +/- SD of quadruplicates. (�) Significant differ-
ences (Student’s t-test, P<0.05) respect to the corresponding WT cells.
(TIF)
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